BIIB News and Press, Biogen Inc. From 02/06/24

2024-02-06 06:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-31 09:54:28 ET More on Biogen Biotech And Pharma Diversification Pays Off Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen slips as UBS cuts to Neutral on Alzheimer’s drug...

Company to reprioritize resources allocated to ADUHELM ® (aducanumab-avwa) to advance LEQEMBI ® (lecanemab-irmb) and to develop new treatment modalities Biogen committed to building a leading Alzheimer’s disease franchise to address patient needs CAMBRIDGE, Mass...

2024-01-30 16:23:19 ET Summary Anti-amyloid drugs likely have little effect on non-APOE4 carriers. Anti-amyloid antibody drugs may have an effect on APOE4 carriers, but with serious and potentially fatal side effects. Safety issues, including potential adverse brain events, ma...

2024-01-29 15:13:38 ET More on Karuna Therapeutics Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript M&A activity expected to pick up in 2024, banke...

2024-01-28 12:00:53 ET More on Amgen, Vertex Pharma, etc. Biotech And Pharma Diversification Pays Off Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar...

2024-01-26 13:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-25 08:00:00 ET Summary Alex Carchidi calls the biotech sector highly risky and speculative, and says diversification is key for investors. Funding is currently difficult to obtain in the biotech industry, but a turnaround is expected. Competitive stories in gene editin...

2024-01-24 08:54:54 ET More on Biogen, Eisai Co., Ltd., etc. Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript) Eisai...

2024-01-22 13:17:30 ET Summary Today, we take a deeper look at Sage Therapeutics, Inc., a biopharmaceutical company focused on developing brain health medicines. The stock has fallen sharply since June on a more limited FDA approval for the company's primary drug candidate. Th...